As of June 10, 2025, MEI Pharma Inc (MEIP) reports a Net Margin of 27.23%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of MEI Pharma Inc's Net Margin
Over recent years, MEI Pharma Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-06-30 | 27.23% |
| 2023-06-30 | -65.22% |
| 2022-06-30 | -133.78% |
| 2021-06-30 | -118.71% |
| 2020-06-30 | -169.92% |
This steady improvement highlights how MEI Pharma Inc manages its overall profitability and cost control over time.
Comparing MEI Pharma Inc's Net Margin to Peers
To better understand MEI Pharma Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| MEI Pharma Inc (MEIP) | 27.23% |
| ADMA Biologics Inc (ADMA) | 46.35% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
Compared to its competitors, MEI Pharma Inc's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.